Enochian Biosciences Inc. [NASDAQ: ENOB] gained 53.97% or 2.38 points to close at $6.79 with a heavy trading volume of 105362016 shares. The company report on June 14, 2021 that Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules.
(NASDAQ: ENOB) — Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that it has entered into a definitive securities purchase agreement with several institutional investors for the issuance and sale of an aggregate of 3,866,667 shares of its common stock at a purchase price of $7.50 per share of common stock a registered direct offering priced at-the-market under Nasdaq rules. The registered direct offering is expected to close on or about June 16, 2021, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
It opened the trading session at $11.88, the shares rose to $12.99 and dropped to $6.71, the range by which the price of stock traded the whole day. The daily chart for ENOB points out that the company has recorded 126.33% gains over the past six months. However, it is still -161.15% lower than its most recent low trading price.
If we look at the average trading volume of 259.93K shares, ENOB reached to a volume of 105362016 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Enochian Biosciences Inc. [ENOB]:
The Average True Range (ATR) for Enochian Biosciences Inc. is set at 0.85 The Price to Book ratio for the last quarter was 1.96, with the Price to Cash per share for the same quarter was set at 0.09.
Trading performance analysis for ENOB stock
Enochian Biosciences Inc. [ENOB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 53.62. With this latest performance, ENOB shares gained by 84.01% in over the last four-week period, additionally plugging by 126.33% over the last 6 months – not to mention a rise of 74.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENOB stock in for the last two-week period is set at 85.42, with the RSI for the last a single of trading hit 89.26, and the three-weeks RSI is set at 81.04 for Enochian Biosciences Inc. [ENOB]. The present Moving Average for the last 50 days of trading for this stock 3.72, while it was recorded at 4.92 for the last single week of trading, and 3.53 for the last 200 days.
Enochian Biosciences Inc. [ENOB]: A deeper dive into fundamental analysis
Return on Total Capital for ENOB is now -6.87, given the latest momentum, and Return on Invested Capital for the company is -6.59. Return on Equity for this stock declined to -6.73, with Return on Assets sitting at -6.38. When it comes to the capital structure of this company, Enochian Biosciences Inc. [ENOB] has a Total Debt to Total Equity ratio set at 4.56. Additionally, ENOB Total Debt to Total Capital is recorded at 4.36, with Total Debt to Total Assets ending up at 4.26. Long-Term Debt to Equity for the company is recorded at 4.40, with the Long-Term Debt to Total Capital now at 4.21.
Reflecting on the efficiency of the workforce at the company, Enochian Biosciences Inc. [ENOB] managed to generate an average of -$1,141,636 per employee.Enochian Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.50.
An analysis of insider ownership at Enochian Biosciences Inc. [ENOB]
There are presently around $18 million, or 5.70% of ENOB stock, in the hands of institutional investors. The top three institutional holders of ENOB stocks are: BLACKROCK INC. with ownership of 962,528, which is approximately 16.737% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 326,318 shares of the stock with an approximate value of $2.22 million in ENOB stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $2.0 million in ENOB stock with ownership of nearly 3.593% of the company’s market capitalization.
21 institutional holders increased their position in Enochian Biosciences Inc. [NASDAQ:ENOB] by around 428,510 shares. Additionally, 15 investors decreased positions by around 161,821 shares, while 8 investors held positions by with 2,122,975 shares. The mentioned changes placed institutional holdings at 2,713,306 shares, according to the latest SEC report filing. ENOB stock had 4 new institutional investments in for a total of 176,195 shares, while 4 institutional investors sold positions of 100,942 shares during the same period.